NASH Pipeline

 

The key companies such as Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others are involved in developing drugs for Non-Alcoholic Steatohepatitis.

The Non-Alcoholic Steatohepatitis report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The report also highlights the unmet needs concerning the development of Non-Alcoholic Steatohepatitis. 

Some of the key highlights of the Non-Alcoholic Steatohepatitis Pipeline Report

  • Resmetirom (MGL-3196) is a first-in-class, orally-administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist.
  • 348 patients were screened and 84 were randomly assigned to resmethrin and 41 to placebo at 18 sites in the USA.
  • Key Players Involved in the Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others.

Request for Sample @ Non-Alcoholic Steatohepatitis Pipeline Insights

Non-Alcoholic Steatohepatitis Overview

Non-Alcoholic Steatohepatitis, liver inflammation, and damage caused by a buildup of fat in the liver. Nonalcoholic fatty liver disease (NAFLD) is an umbrella term for a range of liver conditions. The more severe form of NAFLD is called nonalcoholic steatohepatitis (NASH).

NASH Emerging Therapy: Drug Profile

MGL-3196: Madrigal Pharmaceuticals

Resmetirom neither suppresses the central thyroid axis nor THR-α effects on heart rate or bone, and it reduces elevated liver enzymes in NASH patients. Madrigal Pharmaceuticals plans to submit a marketing approval application in Non-alcoholic steatohepatitis to the US FDA.

Know More Information @ NASH Pipeline Drugs

Key Pipeline Therapies along with companies

  • MGL-3196: Madrigal Pharmaceuticals
  •  Oltipraz: Pharmaking
  • TERN-101:Terns Pharmaceuticals
  • EYP001: ENYO Pharma
  • ZSP-1601: Guangdong Zhongsheng Pharmaceutical
  • ALN-HSD: Alnylam Pharmaceuticals
  • AZF-2693: AstraZeneca

 

NASH Therapeutics Assessment

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

 

By Route of Administration

  • Intravenous
  • Inhalation
  • Oral
  • Subcutaneous 

 

By Molecule Type 

  • Small Molecule 
  • Gene Therapy
  • Stem Cell Therapy

 

By Mechanism of Action

  • Protease Inhibitors
  • Immunomodulatory

 

By Targets

  • Protease 
  • Immune System

 

Contact Here for More Information @ NASH Pipeline Assessment

Scope of NASH Pipeline Report

  • Coverage- Global
  • Key Market Players-Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others.
  • Key NASH Pipeline Therapies- MGL-3196, Oltipraz, TERN-101, EYP001, ZSP-1601, ALN-HSD, AZF-2693, and many others

 

Following is the Table of Content of the NASH Pipeline Report

1 Report Introduction
2 Non-Alcoholic Steatohepatitis (NASH)
3 Non-Alcoholic Steatohepatitis (NASH) Current Treatment Patterns
4 Non-Alcoholic Steatohepatitis (NASH) – DelveInsight’s Analytical Perspective
5 Therapeutic Assessment
6 Non-Alcoholic Steatohepatitis (NASH) Late Stage Products (Phase-III)
7 Non-Alcoholic Steatohepatitis (NASH) Mid Stage Products (Phase-II)
8 Early Stage Products (Phase-I)
9 Pre-clinical Products and Discovery Stage Products
10 Inactive Products
11 Dormant Products
12 Non-Alcoholic Steatohepatitis (NASH) Discontinued Products
13 Non-Alcoholic Steatohepatitis (NASH) Product Profiles
14 Non-Alcoholic Steatohepatitis (NASH) Key Companies
15 Non-Alcoholic Steatohepatitis (NASH) Key Products
16 Dormant and Discontinued Products
17 Non-Alcoholic Steatohepatitis (NASH) Unmet Needs
18 Non-Alcoholic Steatohepatitis (NASH) Future Perspectives
19 Non-Alcoholic Steatohepatitis (NASH) Analyst Review
20 Appendix
21 Report Methodology

 

Know more of what’s covered in the NASH Pipeline Assessment report

Key Questions Answered in the NASH report

  • What are the current options for Non-Alcoholic Steatohepatitis (NASH) treatment?
  • How many companies are developing therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)? 
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
  • How many Non-Alcoholic Steatohepatitis (NASH) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Non-Alcoholic Steatohepatitis (NASH) market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Non-Alcoholic Steatohepatitis (NASH) therapies? 
  • What are the clinical studies going on for Non-Alcoholic Steatohepatitis (NASH) and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Non-Alcoholic Steatohepatitis (NASH)? 
  • How many patents are granted and pending for the emerging therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)? 

 

Request for demo @ NASH Pipeline and get a walk-through of our report

Related Reports

Uncontrolled Bleeding Market

DelveInsight’ s Uncontrolled Bleeding Market Insights, Epidemiology and Market Forecast – 2030 report.

Post-Operative Nausea & Vomiting  Market 

DelveInsight’ s Postoperative Nausea & Vomiting Market Insights, Epidemiology and Market Forecast – 2030 report.

Heavy Menstrual Bleeding  Market

DelveInsight’ s Heavy Menstrual Bleeding Market Insights, Epidemiology and Market Forecast – 2030 report.

Visit on our blog section-

 

About DelveInsight

DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.

Tags: nonalcoholicsteatohepatitisepidemiologysegmentation, nonalcoholicsteatohepatitispipelinereport, nonalcoholicsteatohepatitispipeline, nonalcoholicsteatohepatitis, nonalcoholicsteatohepatitismarket, nonalcoholicsteatohepatitismarketreport, nonalcoholicsteatohepatitismarketresearch, nonalcoholicsteatohepatitismarketresearchreport, nonalcoholicsteatohepatitisepidemiology

Contact Information:

Shruti Thakur
[email protected]